133 related articles for article (PubMed ID: 23228984)
1. Phase I study of bevacizumab combined with irinotecan and S-1 as second-line chemotherapy in patients with advanced colorectal cancer.
Kusaba H; Esaki T; Kishimoto J; Uchino K; Arita S; Kumagai H; Mitsugi K; Akashi K; Baba E
Cancer Chemother Pharmacol; 2013 Jan; 71(1):29-34. PubMed ID: 23228984
[TBL] [Abstract][Full Text] [Related]
2. A Phase II Trial of Combined Chemotherapy with Oral S-1 and 24-Hour Infusions of Irinotecan plus Bevacizumab in Patients with Metastatic Colorectal Cancer.
Sadahiro S; Suzuki T; Tanaka A; Okada K; Saito G; Kamijo A
Oncology; 2015; 88(6):353-9. PubMed ID: 25592116
[TBL] [Abstract][Full Text] [Related]
3. Phase I/II study of a 3-week cycle of irinotecan and S-1 in patients with advanced colorectal cancer.
Kusaba H; Esaki T; Futami K; Tanaka S; Fujishima H; Mitsugi K; Sakai K; Ariyama H; Tanaka R; Kinugawa N; Ueki T; Mibu R; Baba E; Nakano S; Akashi K
Cancer Sci; 2010 Dec; 101(12):2591-5. PubMed ID: 21077997
[TBL] [Abstract][Full Text] [Related]
4. Phase I/II trial of irinotecan and S-1 combination chemotherapy as a second-line treatment for advanced colorectal cancer.
Takii Y; Yamazaki T; Okada T; Tani T; Funakoshi K; Maruyama S; Hasegawa J; Akazawa K; Hatakeyama K;
Chemotherapy; 2013; 59(5):338-43. PubMed ID: 24820531
[TBL] [Abstract][Full Text] [Related]
5. Phase I clinical and pharmacokinetic/pharmacogenetic study of a triplet regimen of S-1/irinotecan/oxaliplatin in patients with metastatic colorectal or gastric cancer.
Park SR; Hong YS; Lim HS; Seong MW; Kong SY; Kim SY; Park YI; Jung KH
Cancer Chemother Pharmacol; 2013 Nov; 72(5):953-64. PubMed ID: 23982118
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of combined chemotherapy with irinotecan and S-1 (IRIS) plus bevacizumab in patients with inoperable recurrent or advanced colorectal cancer.
Komatsu Y; Yuki S; Sogabe S; Fukushima H; Nakatsumi H; Kobayashi Y; Iwanaga I; Nakamura M; Hatanaka K; Miyagishima T; Kudo M; Munakata M; Meguro T; Tateyama M; Sakata Y
Acta Oncol; 2012 Sep; 51(7):867-72. PubMed ID: 22554343
[TBL] [Abstract][Full Text] [Related]
7. Phase II study of oral S-1 with irinotecan and bevacizumab (SIRB) as first-line therapy for patients with metastatic colorectal cancer.
Yamada Y; Yamaguchi T; Matsumoto H; Ichikawa Y; Goto A; Kato K; Hamaguchi T; Shimada Y
Invest New Drugs; 2012 Aug; 30(4):1690-6. PubMed ID: 21894500
[TBL] [Abstract][Full Text] [Related]
8. Second-line combination chemotherapy of oral S-1 with cisplatin and irinotecan for colorectal cancer resistant to 5-FU.
Tsutsumi S; Yamaguchi S; Ide M; Tsuboi K; Fukasawa T; Yamaki S; Asao T; Kuwano H
Hepatogastroenterology; 2006; 53(68):196-200. PubMed ID: 16608023
[TBL] [Abstract][Full Text] [Related]
9. A phase I/II study of biweekly capecitabine and irinotecan plus bevacizumab as second-line chemotherapy in patients with metastatic colorectal cancer.
Suenaga M; Mizunuma N; Matsusaka S; Shinozaki E; Ozaka M; Ogura M; Chin K; Yamaguchi T
Drug Des Devel Ther; 2015; 9():1653-62. PubMed ID: 25834402
[TBL] [Abstract][Full Text] [Related]
10. S-1 and irinotecan plus bevacizumab as second-line chemotherapy for patients with oxaliplatin-refractory metastatic colorectal cancer: a multicenter phase II study in Japan (KSCC1102).
Miyamoto Y; Tsuji A; Tanioka H; Maekawa S; Kawanaka H; Kitazono M; Oki E; Emi Y; Murakami H; Ogata Y; Saeki H; Shimokawa M; Natsugoe S; Akagi Y; Baba H; Maehara Y
Int J Clin Oncol; 2016 Aug; 21(4):705-712. PubMed ID: 26746689
[TBL] [Abstract][Full Text] [Related]
11. A dose-escalation study of oxaliplatin/capecitabine/irinotecan (XELOXIRI) and bevacizumab as a first-line therapy for patients with metastatic colorectal cancer.
Sato Y; Ohnuma H; Hirakawa M; Takahashi M; Osuga T; Okagawa Y; Murase K; Takada K; Kawano Y; Iyama S; Hayashi T; Sato T; Miyanishi K; Takimoto R; Kobune M; Okita K; Mizuguchi T; Furuhata T; Hirata K; Kato J
Cancer Chemother Pharmacol; 2015 Mar; 75(3):587-94. PubMed ID: 25577134
[TBL] [Abstract][Full Text] [Related]
12. A phase I study of combination therapy with S-1 and irinotecan in patients with previously untreated metastatic or recurrent colorectal cancer.
Choi YH; Kim TW; Lee SS; Hong YS; Ryu MH; Lee JL; Chang HM; Kang YK
Cancer Chemother Pharmacol; 2011 Oct; 68(4):905-12. PubMed ID: 21290246
[TBL] [Abstract][Full Text] [Related]
13. A dose-finding study for oxaliplatin, irinotecan, and S-1 (OIS) in patients with metastatic or recurrent gastrointestinal cancer.
Han B; Jung JY; Kim HS; Cho JW; Kim KC; Lim H; Kang HS; Ha HI; Kim MJ; Kim JH; Choi DR; Jang G; Kim JH; Song H; Zang DY
Cancer Chemother Pharmacol; 2016 Nov; 78(5):949-958. PubMed ID: 27628195
[TBL] [Abstract][Full Text] [Related]
14. Phase I study of S-1 combined with irinotecan (CPT-11) in patients with advanced colorectal cancer.
Tsunoda A; Yasuda N; Nakao K; Narita K; Yamazaki K; Watanabe M; Suzuki N; Kusano M
Oncology; 2007; 72(1-2):58-63. PubMed ID: 17998791
[TBL] [Abstract][Full Text] [Related]
15. Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study).
Muro K; Boku N; Shimada Y; Tsuji A; Sameshima S; Baba H; Satoh T; Denda T; Ina K; Nishina T; Yamaguchi K; Takiuchi H; Esaki T; Tokunaga S; Kuwano H; Komatsu Y; Watanabe M; Hyodo I; Morita S; Sugihara K
Lancet Oncol; 2010 Sep; 11(9):853-60. PubMed ID: 20708966
[TBL] [Abstract][Full Text] [Related]
16. A phase II study of bevacizumab and irinotecan plus alternate-day S-1 as a second-line therapy in patients with metastatic colorectal cancer: the AIRS study.
Matsuda C; Honda M; Tanaka C; Kondo K; Takahashi T; Kosugi C; Tokunaga Y; Takemoto H; Kim HM; Sakamoto J; Oba K; Mishima H
Cancer Chemother Pharmacol; 2018 Jun; 81(6):1035-1041. PubMed ID: 29644459
[TBL] [Abstract][Full Text] [Related]
17. Dosage escalation study of S-1 and irinotecan in metronomic chemotherapy against advanced colorectal cancer.
Ogata Y; Sasatomi T; Akagi Y; Ishibashi N; Mori S; Shirouzu K
Kurume Med J; 2009; 56(1-2):1-7. PubMed ID: 20103995
[TBL] [Abstract][Full Text] [Related]
18. Phase I trial of neoadjuvant preoperative chemotherapy with S-1 and irinotecan plus radiation in patients with locally advanced rectal cancer.
Sato T; Kokuba Y; Koizumi W; Hayakawa K; Okayasu I; Watanabe M
Int J Radiat Oncol Biol Phys; 2007 Dec; 69(5):1442-7. PubMed ID: 17855009
[TBL] [Abstract][Full Text] [Related]
19. Phase I and pharmacokinetic study of the oral fluoropyrimidine S-1 on a once-daily-for-28-day schedule in patients with advanced malignancies.
Chu QS; Hammond LA; Schwartz G; Ochoa L; Rha SY; Denis L; Molpus K; Roedig B; Letrent SP; Damle B; DeCillis AP; Rowinsky EK
Clin Cancer Res; 2004 Aug; 10(15):4913-21. PubMed ID: 15297391
[TBL] [Abstract][Full Text] [Related]
20. Phase II study of combination therapy with S-1 and irinotecan in patients with advanced colorectal cancer.
Goto A; Yamada Y; Yasui H; Kato K; Hamaguchi T; Muro K; Shimada Y; Shirao K
Ann Oncol; 2006 Jun; 17(6):968-73. PubMed ID: 16603600
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
